Advanced Nanosystems and Emerging Therapies: Innovations in Tuberculosis Treatment and Drug Resistance
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".
Deadline for manuscript submissions: closed (29 August 2025) | Viewed by 1447
Special Issue Editor
Interests: mycobacterium tuberculosis; new drugs; biological assays; antibiotics; antibiotics resistance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Nanotechnology has emerged as a transformative force in the fight against tuberculosis (TB), a disease that continues to challenge global health, particularly with the rise of multidrug-resistant Mycobacterium tuberculosis (MDR-TB). Conventional therapies often suffer from limitations such as poor bioavailability, long treatment durations, and adverse side effects. Nanosystems, through their capacity for targeted drug delivery, enhanced bioavailability, and reduced toxicity, offer promising solutions to overcome these barriers. Recent advancements in nanosystems have shown potential not only in delivering existing anti-TB drugs more effectively but also in the development of new therapeutic strategies and vaccines.
We are pleased to invite you to contribute to this Special Issue which focuses on the potential of nanosystems in antituberculosis therapy. This collection of papers will highlight the latest scientific developments in the use of nanotechnology to improve TB treatment outcomes, especially in addressing drug resistance and minimizing side effects, aligning with the journal’s commitment to publishing cutting-edge research in the field of tuberculosis therapy.
This Special Issue aims to gather innovative research on the application of nanosystems in the treatment of TB. The goal is to present a collection of original research articles and reviews that contribute to advancing nanotechnology-based therapies and their translation into clinical settings. This topic fits within the journal’s scope by exploring novel approaches to TB treatment through interdisciplinary collaboration in pharmaceutical sciences, nanomedicine, and microbiology.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following themes:
- Nanoparticle-based drug delivery systems targeting Mycobacterium tuberculosis;
- The development of liposomes, dendrimers, and polymeric nanoparticles for TB therapy;
- Nanocarriers designed to enhance intracellular delivery of anti-TB drugs;
- Overcoming drug resistance through nanotechnology-enhanced therapeutics;
- The pharmacokinetics and bioavailability of nanomedicines for TB;
- The safety, toxicity, and immune responses related to nanosystems in TB treatment;
- Preclinical and clinical studies on nanotechnology in TB therapy;
- Nanotechnology-enhanced vaccines for tuberculosis;
- In silico studies of new anti-TB agents.
We look forward to receiving your valuable contributions.
Dr. Fernando Rogério Pavan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanosystems
- tuberculosis therapy
- drug delivery
- multidrug-resistant Mycobacterium tuberculosis (MDR-TB)
- nanotechnology-based therapeutics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
